203 related articles for article (PubMed ID: 24187487)
1. Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells.
Cheng M; Xu H; Wang Y; Chen H; He B; Gao X; Li Y; Han J; Zhang Z
Drug Des Devel Ther; 2013; 7():1287-99. PubMed ID: 24187487
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.
Cheng M; Gao X; Wang Y; Chen H; He B; Xu H; Li Y; Han J; Zhang Z
Mar Drugs; 2013 Sep; 11(9):3517-36. PubMed ID: 24048270
[TBL] [Abstract][Full Text] [Related]
3. Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics.
Cheng M; Chen H; Wang Y; Xu H; He B; Han J; Zhang Z
Int J Nanomedicine; 2014; 9():695-710. PubMed ID: 24493926
[TBL] [Abstract][Full Text] [Related]
4. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
Cheng M; Ma D; Zhi K; Liu B; Zhu W
Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of galactosylated chitosan/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies.
Cheng M; Han J; Li Q; He B; Zha B; Wu J; Zhou R; Ye T; Wang W; Xu H; Hou Y
J Biomed Mater Res B Appl Biomater; 2012 Nov; 100(8):2035-43. PubMed ID: 22865703
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhetinic acid modified MOFs for the treatment of liver cancer.
Li L; Han S; Yang C; Liu L; Zhao S; Wang X; Liu B; Pan H; Liu Y
Nanotechnology; 2020 Aug; 31(32):325602. PubMed ID: 32320964
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo.
Cheng M; Gao X; Wang Y; Chen H; He B; Li Y; Han J; Zhang Z
Int J Nanomedicine; 2013; 8():4265-76. PubMed ID: 24232303
[TBL] [Abstract][Full Text] [Related]
9. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
Cheng M; He B; Wan T; Zhu W; Han J; Zha B; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
PLoS One; 2012; 7(10):e47115. PubMed ID: 23077553
[TBL] [Abstract][Full Text] [Related]
12. Characterization of chitosan-carboxymethyl dextran nanoparticles as a drug carrier and as a stimulator of mouse splenocytes.
Lin YS; Radzi R; Morimoto M; Saimoto H; Okamoto Y; Minami S
J Biomater Sci Polym Ed; 2012; 23(11):1401-20. PubMed ID: 21740648
[TBL] [Abstract][Full Text] [Related]
13. Insight into glycyrrhetinic acid: the role of the hydroxyl group on liver targeting.
Tian Q; Wang X; Wang W; Zhang C; Liu Y; Yuan Z
Int J Pharm; 2010 Nov; 400(1-2):153-7. PubMed ID: 20813176
[TBL] [Abstract][Full Text] [Related]
14. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
Cheng M; Liu Z; Wan T; He B; Zha B; Han J; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
Cancer Biol Ther; 2012 Dec; 13(14):1407-16. PubMed ID: 22954702
[TBL] [Abstract][Full Text] [Related]
15. Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice.
Zhang DY; Shen XZ; Wang JY; Dong L; Zheng YL; Wu LL
World J Gastroenterol; 2008 Jun; 14(22):3554-62. PubMed ID: 18567086
[TBL] [Abstract][Full Text] [Related]
16. Assessment of sequential combination of 5-fluorouracil-loaded-chitosan-nanoparticles and ALA-photodynamic therapy on HeLa cell line.
Benito-Miguel M; Blanco MD; Gómez C
Photodiagnosis Photodyn Ther; 2015 Sep; 12(3):466-75. PubMed ID: 25976508
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronidase enzyme core-5-fluorouracil-loaded chitosan-PEG-gelatin polymer nanocomposites as targeted and controlled drug delivery vehicles.
Rajan M; Raj V; Al-Arfaj AA; Murugan AM
Int J Pharm; 2013 Sep; 453(2):514-22. PubMed ID: 23796828
[TBL] [Abstract][Full Text] [Related]
19. Cytocompatible chitosan-graft-mPEG-based 5-fluorouracil-loaded polymeric nanoparticles for tumor-targeted drug delivery.
Antoniraj MG; Ayyavu M; Henry LJK; Nageshwar Rao G; Natesan S; Sundar DS; Kandasamy R
Drug Dev Ind Pharm; 2018 Mar; 44(3):365-376. PubMed ID: 28835136
[TBL] [Abstract][Full Text] [Related]
20. Enhancing therapeutic efficacy: sustained delivery of 5-fluorouracil (5-FU) via thiolated chitosan nanoparticles targeting CD44 in triple-negative breast cancer.
Anjum S; Naseer F; Ahmad T; Jahan F; Qadir H; Gul R; Kousar K; Sarwar A; Shabbir A
Sci Rep; 2024 May; 14(1):11431. PubMed ID: 38763930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
